Profusa Inc

PFSA

Market cap $13M

Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO ₂ ) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights (PVI) 2025, being held on December 11-13, 2025, in Paris, France. Presentation: Title Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)     Presenter Peter Schneider, M.D.

Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights. Ben Hwang, Ph.D.

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform

Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets BERKELEY, Calif, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces completion of key manufacturing initiatives to support 2026 Lumee™ tissue oxygen monitoring revenue targets.  “Our team is laser-focused on achieving revenue from sales of Lumee™ tissue oxygen monitoring systems to our customers in the beginning of the second quarter of 2026.

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the Company's treasury management strategy.

Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces additional growth in its customer base in Europe, with a collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI).

Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows

Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care